FDA responds to some unacceptable structure/function claims with "courtesy" letters.
This article was originally published in The Tan Sheet
Executive Summary
STRUCTURE/FUNCTION NOTIFICATIONS HAVE GENERATED FDA "COURTESY" LETTERS in "a couple of cases" to manufacturers registering structure/function claims that were "treatment claims for a disease condition," FDA Office of Special Nutritionals Director Elizabeth Yetley, PhD, told the Commission on Dietary Supplement Labels on Feb. 16. Yetley spoke at the commission's inaugural meeting in Washington, D.C.